Cosmo Pharmaceuticals N.V.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Cosmo Pharmaceuticals N.V.
Private Company Edition: The global accelerator has new commitments from HHS and the Wellcome Trust. Also, Apollo buys into Sofinnova Partners with an up to €1bn investment, Castle Creek raised $124.6m in private funding this year in lieu of an IPO and Remix closed a $70m series B round.
Licensing deals and partnerships carried the day during another hectic J.P. Morgan Healthcare Conference. Pfizer racked up its third deal of the week in a cancer collaboration with Dren Bio.
Digital Health Roundup, April 2021: Digital Transformation In OR, Clinical Trials, Remote Monitoring
In this new roundup feature focusing on the most notable developments in digital health, we pick the key news from April.
According to a large clinical study, the first such device with AI-enabled software is better at detecting potential lesions than traditional colonoscopies and could allow detection of colon cancer sooner.
- Specialty Pharmaceuticals
- Controlled Release
- Other Names / Subsidiaries
- Aries Group, Ltd
- Aries Pharmaceuticals, Inc.
- Cosmo Technologies Limited
- Cosmo Pharmaceuticals S.p.A.